Clinical trial
Phase II Study With Catumaxomab in Patients With Gastric Cancer After…
NCT00464893 · Neovii Biotech, Industry · Completed
Key facts
| NCT number | NCT00464893 |
|---|---|
| Title | Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection |
| Official title | Multicenter, Open-label Phase II Study to Evaluate the Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients With Gastric Adenocarcinoma After Neoadjuvant Chemotherapy and Intended Curative Resection |
| Lead sponsor | Neovii Biotech, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Gastric Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Catumaxomab, catumaxomab |
| Enrollment | 70 |
| Start date | Apr 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2013 |
| First posted | Apr 24, 2007 |
| Last update posted | Dec 4, 2013 |
| Countries | Austria, Germany, Spain, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: